# Scribe Therapeutics Inc. (SCTX)

Source: https://www.quantisnow.com/company/SCTX
Generated: 2026-11-14T09:54:30.399Z

- Ticker: SCTX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2026
- SEC CIK: 0001853921
- Website: https://www.scribetx.com/

## About

Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design approach and nature's blueprint for improved cardiovascular health, Scribe's initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The company's lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly.

## Latest SCTX news and filings

- 2026-11-12 21:22 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Scribe Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-scribe-therapeutics-inc-6788267)
- 2026-11-12 21:20 UTC [SEC Form 8-K] [Scribe Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/scribe-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6788226)
- 2026-11-12 21:05 UTC [Earnings] [Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights](https://www.quantisnow.com/insight/scribe-therapeutics-reports-third-quarter-2026-financial-results-and-recent-6787657)
- 2026-11-05 13:00 UTC [Conference Announcement] [Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences](https://www.quantisnow.com/insight/scribe-therapeutics-to-participate-in-upcoming-healthcare-investor-conferences-6774806)
- 2026-11-04 13:00 UTC [Conference Announcement] [Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026](https://www.quantisnow.com/insight/scribe-therapeutics-to-present-updated-data-on-pcsk9-targeting-epigenetic-silencing-6771426)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/SCTX
- Earnings history: https://www.quantisnow.com/earnings/SCTX
- Dividend history: https://www.quantisnow.com/dividends/SCTX
- Insider transactions: https://www.quantisnow.com/insiders/SCTX
- Options chain: https://www.quantisnow.com/options/SCTX
- SEC 8-K filings only: https://www.quantisnow.com/company/SCTX/8-k
- RSS and alerts for SCTX: https://www.quantisnow.com/docs/rss-feeds.md